Medical Research

Partnership for Cures

Delivering More Treatments to More Patients More Quickly

aka Cures Within Reach



Cures Within Reach improves patient quality and length of life by leveraging the unrealized clinical potential and missed therapeutic opportunities of existing medicine and science. We leverage the speed, safety and cost-effectiveness of medical repurposing research, driving more treatments to more patients more quickly by clinically testing approved drugs, devices and nutraceuticals for unsolved disease indications that serve commercial and/or philanthropic need.

Notes from the Nonprofit

The more we work together, the sooner we can drive more treatments to more patients more quickly through Repurposing Research.

Ruling Year



Barbara Goodman

Main Address

134 N. LaSalle St #1130



disease, cancer, foundation, fundraising, venture philanthropy, research, innovation, medical, Rediscovery Research™, health care, repurposing, repositioning, drug, device, treatment, cure,





Cause Area (NTEE Code)

Medical Specialty Research (H90)

Fund Raising and/or Fund Distribution (G12)

Research Institutes and/or Public Policy Analysis (E05)

IRS Filing Requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2018, 2017 and 2016.
Register now

Social Media

Programs + Results

What we aim to solve

There are 7000+ unsolved diseases, and de novo drug discovery can't provide affordable treatments for all of these. Drug and other therapeutic repurposing can provide "new" therapies, but there is a lack of economic incentives and governmental programs to encourage drug and other repurposing.

Our programs

What are the organization's current programs, how do they measure success, and who do the programs serve?

SOURCE: Self-reported by organization

Proof of Concept Clinical Trials


New Economic Engines for Generic Drug Repurposing

Where we work

Charting Impact

Five powerful questions that require reflection about what really matters - results.

SOURCE: Self-reported by organization

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

How will they know if they are making progress?

What have they accomplished so far and what's next?

Our goal is to create hundreds of "new" therapies through the repurposing of existing drugs, devices, nutriceuticals and diagnostics on a global basis. We want to create platforms for collaboration, and engines for economic support for Repurposing Research.

Strategy 1: Grow the CureAccelerator™ web platform to provide the collaboration tool and Repurposing Research marketplace that provides the many to many connections and ease of use for Repurposing Research to get funded and completed and delivered to patents.

Strategy 2: Create new economic engines for the repurposing of generic drugs for off-label use through social finance tools and through generic drug company partnerships that can support philanthropic funding, and through low profit commercialization that can support the regulatory approval for marketed generic drugs.

We already have developed CureAccelerator™ funded by a grant from the Robert Wood Johnson Foundation, and we now need to grow it.

We have structured and pursued the first social impact bond in England with our partners FindaCure and Numbers4Good. We have completed feasibility studies from the MaRS Centre funded by the Mindset Foundation and by Oliver Wyman supporting FindaCure.

We have support for the feasibility studies on the low profit commercialization program, and we have started discussions with generic drug companies.

We are supported by a Business Advisory Board comprised of senior staff from many of the stakeholders involved in Repurposing Research.

The single measure of our work is the number of affordable and effective repurposed treatments made available to patients.

For over a decade, Cures WIthin Reach has found and funded over 85 repurposing research projects in over 50 institutions in 50 different diseases. This has resulted in supporting research that found 13 repurposed therapies for children with deadly diseases ALPS and FD, adults with multiple sclerosis, lung cancer, blood cancer, myelodysplastic syndrome and prostate cancer, and adult and children with type 1 and type 2 diabetes. Our $6 million in funding has helped to catalyze more than $49 million in follow-on funding - a strong leverage metric. We have a strong platform called CureAccelerator™ where researchers and clinicians submit their clinical repurposing research ideas for funding.

External Reviews


Fellowship in Social Entrepreneurship 2009



Partnership for Cures

Need more info on this nonprofit?

Need more info on this nonprofit?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2018, 2017 and 2016
  • A Pro report is also available for this organization.

See what's included


The people, governance practices, and partners that make the organization tick.

Need more info?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2018, 2017 and 2016
  • A Pro report is also available for this organization.

See what's included

Board Leadership Practices

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section, which enables organizations and donors to transparently share information about essential board leadership practices.

SOURCE: Self-reported by organization


Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations?



Has the board conducted a formal, written assessment of the chief executive within the past year?



Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year?



Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership?



Has the board conducted a formal, written self-assessment of its performance within the past three years?


Organizational Demographics

In order to support nonprofits and gain valuable insight for the sector, GuideStar worked with D5—a five-year initiative to advance diversity, equity, and inclusion in philanthropy—in creating a questionnaire. This section is a voluntary questionnaire that empowers organizations to share information on the demographics of who works in and leads organizations. To protect the identity of individuals, we do not display sexual orientation or disability information for organizations with fewer than 15 staff. Any values displayed in this section are percentages of the total number of individuals in each category (e.g. 20% of all Board members for X organization are female).

SOURCE: Self-reported by organization


Race & Ethnicity

This organization reports that it does not collect this information for Board Members.

Sexual Orientation

This organization reports that it does not collect this information.


We do not display disability information for organizations with fewer than 15 staff.

Diversity Strategies

We track retention of staff, board, and volunteers across demographic categories
We track income levels of staff, senior staff, and board across demographic categories
We track the age of staff, senior staff, and board
We track the diversity of vendors (e.g., consultants, professional service firms)
We have a diversity committee in place
We have a diversity manager in place
We have a diversity plan
We use other methods to support diversity